R&D expense · 2011–2025
Elite Pharmaceuticals R&D expense
$5.7M−27.9% · FY2025
Elite Pharmaceuticals (ELTP) reported $5.7M in R&D expense for fiscal 2025, −27.9% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252026-03-31 | $5.7M | −27.9% | Open → |
| FY20242025-03-31 | $8.0M | +15.7% | Open → |
| FY20232024-03-31 | $6.9M | +11.0% | Open → |
| FY20222023-03-31 | $6.2M | +53.0% | Open → |
| FY20212022-03-31 | $4.1M | −20.8% | Open → |
| FY20202021-03-31 | $5.1M | −7.6% | Open → |
| FY20192020-03-31 | $5.5M | −27.2% | Open → |
| FY20182019-03-31 | $7.6M | −21.0% | Open → |
| FY20172018-03-31 | $9.6M | +15.9% | Open → |
| FY20162017-03-31 | $8.3M | −33.2% | Open → |
| FY20152016-03-31 | $12.4M | −15.6% | Open → |
| FY20142015-03-31 | $14.7M | +272.0% | Open → |
| FY20132014-03-31 | $4.0M | +306.0% | Open → |
| FY20122013-03-31 | $975,250 | −43.8% | Open → |
| FY20112012-03-31 | $1.7M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +8.9%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Elite Pharmaceuticals R&D expense |url=https://companiesranked.com/en/company/elite-pharmaceuticals/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Elite Pharmaceuticals R&D expense. CompaniesRanked. https://companiesranked.com/en/company/elite-pharmaceuticals/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-elite-pharmaceuticals-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Elite Pharmaceuticals R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/elite-pharmaceuticals/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001493152-26-031070 · June 29, 2026
{{cite web |title=Elite Pharmaceuticals R&D expense — 10-K (0001493152-26-031070) |url=https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-06-29}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.